000			a
999			_c18962 _d18962
003			OSt
005			20230302113321.0
008			230302b xxu||||| |||| 00| 0 eng d
040			_aAIKTC-KRRC _cAIKTC-KRRC
100			_94115 _aShete, A. S.
245			_aFenofibrate-nicotinamide cocrystals: molecular docking studies and evaluation in tablet dosage form
250			_aVol.84(3), May-Jun
260			_aMumbai _bIndian Journal of Pharmaceutical Science _c2022
300			_a560-568p.
520			_aThe objectives of present investigation were to evaluate prepared cocrystals of fenofibrate and nicotinamide for pre-compression characteristics, docking studies for target peroxisome proliferator-activated receptor alpha, evaluate performance of cocrystals in tablet dosage form and to carry out in vivo antihyperlipidemic activity. The cocrystals were prepared by antisolvent addition method. Docking studies of cocrystals and pure fenofibrate against of target peroxisome proliferator-activated receptor alpha were carried out by using PyRx (version 0.8) docking tool, AutoDock Vina as docking program. The prepared cocrystals were evaluated for pre-compression properties like angle of repose, bulk density and Carr’s index. Cocrystals were formulated in tablet dosage form and evaluated for official and unofficial quality control tests. The antihyperlipidemic activity carried out in rats by using Triton X-100 induced hyperlipidemia model. Cocrystals binds with peroxisome proliferator-activated receptor alpha with more binding affinity as compared with fenofibrate. Cocrystal shows binding energy of -9.3 kcal/mol while fenofibrate shows -8.5 kcal/mol. The pre-compression properties were within the limits of United States Pharmacopeia guidelines. The pure fenofibrate tablet showed 24.7 % drug release at the end of 90 min and cocrystal based tablet showed 100 % at 45 min. There was no statistically significant difference in values for all biochemical parameters in case of in vivo activity for cocrystals in comparison with pure fenofibrate. From the docking studies we can conclude that cocrystals showed stronger more substantial formed stable complexes with target peroxisome proliferator-activated receptor alpha, but no statistically significant difference in pharmacodynamic studies.
650		0	_94639 _aPHARMACEUTICS
700			_920150 _aShah, V. V.
773	0		_tIndian journal of pharmaceutical sciences _dNew Delhi Indian Pharmaceutical Association _x0250-474X
856			_uhttps://www.ijpsonline.com/articles/fenofibratenicotinamide-cocrystals-molecular-docking-studies-and-evaluation-in-tablet-dosage-form-4618.html _yClick here
942			_2ddc _cAR